Kamada is focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

Read more


Here you can find information about Kamada's board of directors and its experienced senior management team.

Read more


  • To develop and produce top quality pharmaceuticals while ensuring GMP quality principle.
  • To penetrate U.S and Europe markets, based on strategic partnerships and competitive advantage.
  • To preserve and promote our status as a leading manufacturer and distributer, to the benefit of our satisfied customers.


Read more


Kamada’s philosophy embraces the joining of forces with industry partners. As each partner brings unique strengths and abilities into the partnership, a greater whole is created. 

Read more


Kamada, as a leading pharmaceutical company, sees the great importance of supporting and promoting social responsibility: The Company's operations are based on values of quality and excellence, including saving lives, quality of life, healthcare and contribution to the community.

Kamada sees itself as an integral part of the community within which it operates, and therefore allocates significant resources to assist a great number of non-profit organizations, families and individuals – seeking to contribute to community and individual well-being as well as to social advancement.

Read more


Kamada has grown its business over time, thanks to the vision, skills and outstanding dedication of its employees.

Kamada believes that being the first Israeli company ever to obtain FDA approval for a biological drug, as well as its capacity to develop, produce and market a range of life-saving drugs around the world, provide the basis for Kamada's current and future success.


Read more